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Abstract.  Endothelial cell growth factor (ECGF) is a 
potent polypeptide mitogen for endothelial cells and 
fibroblasts.  The mitogenic effects of ECGF are in- 
hibited by the lymphokine gamma-interferon (gamma- 
IFN) in a  dose-dependent manner.  Gamma-IFN also 
induces a unique change in endothelial cell morphol- 
ogy which is maximally expressed in the presence of 
ECGE  The antiproliferative and phenotypic modula- 
tory effects of gamma-IFN on endothelial cells are re- 
versible.  Inhibition of ECGF-induced endothelial cell 
proliferation by gamma-IFN is accompanied by a 
concentration- and time-dependent decrease in binding 
of ~25I-ECGF to the endothelial cell surface. Scatchard 
analyses of the binding data in the presence and ab- 
sence of gamma-IFN demonstrate a decrease in the 
number of ECGF-binding sites rather than a  decrease 
in ligand affinity for the receptor.  Cross-linking ex- 
periments with disuccinimidyl suberate demonstrate a 
decrease in the  170,000 Mr cross-linked receptor-ligand 
complex. These data suggest that gamma-IFN inhibits 
endothelial cell proliferation by a  mechanism which 
involves growth factor receptor modulation. 
T 
aB endothelial cell participates in neovascularization, 
a phenomenon which includes the formation of new 
blood vessels in response to a variety of normal and 
pathological situations (6,  7,  9,  16). Although the mecha- 
nisms of angiogenesis are not defined, an important compo- 
nent of the process is the migration and proliferation of the 
endothelial cell. The stimulation of neovascularization under 
a rather broad set of circumstances and conditions demon- 
strates the fundamental importance of this phenomenon to 
our  understanding  of  human  physiology and  pathology. 
Thus, it is important to identify specific modulators of en- 
dothelial cell migration and proliferation since this behavior 
underlies the angiogenic process. 
Alpha-endothelial cell growth factor (ECGF) 1 is a mem- 
ber of a family of endothelial cell polypeptide mitogens (27) 
which presently includes beta-ECGE acidic fibroblast growth 
factor (30, 31), eye-derived growth factor II (5), and heparin- 
binding growth factor I (28). This family of endothelial cell 
polypeptide mitogens has also been shown to be angiogenic 
in vivo by the chick chorioallantoic membrane, rabbit cor- 
neal neovascularization (28,  31), and hamster cheek pouch 
assays (Schreiber, A. B., and T. Maciag, unpublished obser- 
vation). The polypeptide, alpha-ECGF, is mitogenic (19) and 
chemotactic (29)  for human endothelial cells in vitro and 
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represents the des 1-21 form ofbeta-ECGF (3). The gene en- 
coding this polypeptide is localized on human chromosome 
5 and encodes a polypeptide which does not contain a se- 
quence equivalent to a traditional signal peptide (13). The 
mitogenic (8, 19, 32) and chemotactic (29) response of alpha- 
ECGF on endothelial cells is potentiated by the glycosami- 
noglycan, heparin, which binds the polypeptide mitogen (19, 
26) and decreases the apparent Kd for receptor occupancy 
(26).  The mitogenic signal which is transduced across the 
endothelial cell plasma membrane involves the noncovalent 
binding of alpha-ECGF to a cell surface-associated polypep- 
tide with an apparent Mr of 150,000 (8). It is also known that 
ligand occupancy of the ECGF receptor induces down-regu- 
lation of the receptor (8, 26), an observation which is consis- 
tent with the behavior of other polypeptide mitogens (12). 
In this report, we demonstrate that the lymphokine, gam- 
ma-interferon (gamma-IFN), inhibits ECGF-induced endo- 
thelial cell proliferation with a concomitant change in endo- 
thelial cell morphology. In addition, we demonstrate that the 
effects of gamma-IFN on ECGF-induced proliferation corre- 
late with a decrease in the number of ECGF receptors on the 
endothelial cell surface. 
Materials and Methods 
Materials 
Human native gamma-IFN (sp act  1.5  x  10  6 U/mg), human recombinant 
gamma-IFN (sp act 1.2  ×  l0  s U/rag), and anti-human gamma-IFN mAb's 
were  a  gift of Dr.  Nava  Sarver  (Meloy  Laboratories,  Inc.)  and  human 
fibronectin was a gift from Dr. Michael Hrinda (Meloy Laboratories, Inc.). 
Crude  ECGF  was  prepared  as  described  (17). Highly  purified  murine 
©  The Rockefeller University Press, 0021-9525/87/03/689/8 $1.00 
The Journal of Cell Biology, Volume 104,  March 1987 689-696  689 gamma-IFN (sp act 6.6  ×  106 U/mg) was a gift of Dr. Sidney Grossberg 
(University of Wisconsin). Recombinant murine gamma-IFN (sp act 1.3 x 
107 U/mg) was a gift of Dr. Dvord Samid (Uniformed Services University 
for Health  Sciences). ECGF was prepared as previously described (2). 
Medium 199 and trypsin-EDTA were purchased from Gibco (Grand Island, 
NY). FBS was purchased from HyClone Laboratories, Sterile Systems, Inc. 
(Logan, UT); tissue culture plasticware was from Costar (Cambridge, MA); 
epidermal growth factor  (EGF)  was purchased  from Collaborative Re- 
search, Inc. (Waltham,  MA); 125I-EGF was a gift of Dr. Towia Libermann 
(Biotechnology  Research Center);  and  heparin  was  from  Upjohn Co., 
(Kalamazoo, MI). Radioisotopes were purchased from New England Nu- 
clear (Boston, MA), and disuccinimidyl suberate (DSS) was from Pierce 
Chemical Co. (Rockford, IL). All electrophoresis reagents were from Brit- 
ish Drug House and other reagents were reagent grade. 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC) were a gift from Dr. M. 
Gimbrone (Harvard Medical School, Boston, MA). HUVEC were cultured 
in Medium 199, 10% (vol/vol) FBS,  100 Ixg/ml crude ECGF, and 5 U/ml 
heparin as previously described (17, 32). HUVEC were used between pas- 
sages 5 and 11 (1:5 split ratio) for all experiments. Murine lung capillary 
endothelial cells  (LEU)  were  obtained  from  Dr.  A.  Schreiber (Meloy 
Laboratories, Inc.) and cultured in DME supplemented with 5% (vol/vol) 
FBS and 5%  (vol/vol) charcoal-treated fetal bovine serum (ChFBS). 
The HUVEC growth assay was performed as previously described (17). 
Briefly, HUVEC (2 ×  104 cells per well) were plated on 35-ram wells pre- 
viously coated with 10 I~g/cm  2 human fibronectin and incubated for 3 d at 
37°C with Medium 199 supplemented with 10%  (vol/vol) FBS. The low 
seed density cultures were incubated with alpha-ECGE garnma-IFN, and 
antibodies at the indicated concentrations and combinations for 10-12 d. 
The biological response modifiers were replaced every 2-3 d during this 
period. At the indicated intervals, duplicate culture dishes were harvested 
by treatment with trypsin-EDTA and the number of viable endothelial cells 
quantitated by counting with a hemocytometer. 
The [3H]thymidine assay was performed using LEII cells as previously 
described (19). Briefly, LEII ceils were seeded into 48-well plates and grown 
to confluence in 0.5 ml DME, 5% FBS, 5% ChFBS. The cells were starved 
for 48 h in 0.5 ml DME supplemented with 0.5% ChFBS. Alpha-ECGF, 
with or without various concentrations of murine native or recombinant 
gamma-IFN, were added and the cells were incubated at 37°C for 18 h. The 
LEII ceils were pulsed with 13H]thymidine (0.5 txCi per well) for 4 h, after 
which the culture dishes were washed with PBS and DNA was precipitated 
with 10% TCA. TCA-precipitable material was solubilized in 0.1 N NaOH 
and radioactivity was measured by liquid scintillation counting as described 
(19). 
ECGF Receptor Binding Assays 
The binding assays were performed essentially as described (26) with minor 
changes. LEII cells were seeded into 24-well tissue culture plates and grown 
to confluence in DME, 5% (vol/vol) FBS, and 5% (vol/vol) ChFBS. The 
cells were starved in DME, 0.5%  ChFBS for 24 h, after which the cells 
were treated with various concentrations of murine gamma-IFN at 37°C, 
with or without 6 nM alpha-ECGF for various time intervals. At the end 
of these treatments, the cells were washed three times with ice cold binding 
buffer (DME containing 25 mM Hepes and 5 mg/ml BSA, pH 7.4) and incu- 
bated at 4°C with 0.2-ml binding buffer containing mI-alpha-ECGF at a final 
concentration of 15 ng/ml unless otherwise noted. Incubations proceeded 
for 2 h at 4°C to allow binding to reach equilibrium after which the medium 
was aspirated and the cells were washed three times with cold binding 
buffer. The cell-associated radioactivity was determined by solubilizing the 
cells in 1.0 ml 0.1 M NaOH. Nonspecific binding was determined by the 
incubation of  125I-alpha-ECGF  with  a  102-fold molar excess unlabeled 
alpha-ECGF, and did not exceed 20%  of the total binding. All reported 
values are corrected for nonspecific binding. Cell numbers were determined 
by harvesting cells by treatment with trypsin-EDTA solution and quanti- 
tated with a  hemocytometer. The cell number after confluence did not 
change significantly over the time interval tested regardless of the addition 
of ECGF or gamma-IFN. 
ECGF was iodinated as previously described (8).  Briefly,  2--4  Ixg of 
alpha-ECGF (protein concentration determined by amino acid analysis) in 
0.1 M sodium phosphate buffer, pH 8.0, received 50 ~tl of Enzymobead (Bio- 
Rad Laboratories, Richmond CA) suspension, 0.5 mCimI and 20 ltl of 
2 mg/ml Beta-o-glucose. The reaction was carried out at 22°C for 5 min. 
The enzymobeads were removed by centrifugation, and free iodine sepa- 
rated from iodinated alpha-ECGF by binding and elution of L25I-alpha- 
ECGF  to  a  0.5-ml  heparin-Sepharose column  equilibrated  in  50  mM 
Tris-HC1,  10 mM EDTA, pH Z3 as described (8).  125I-Alpha-ECGF was 
eluted off heparin-Sepharose with 1.5 M  NaC1 containing 50 mM Tris- 
HCI, pH 7.5, and collected in BSA at a final concentration of 0.1% (wt/~ol). 
125I-ECGF prepared in this manner possesses a specific activity of '~1-2  x 
lri  s cpm/ng, and is >95% precipitable with 10% (wt/vol) TCA.  125I-Alpha- 
ECGF retains full biological activity as determined by [3H]thymidine  as- 
say using LEII cells (8).  Both native alpha-ECGF and  12sI-alpha-ECGF 
give half maximal stimulation of [3H]thymidine incorporation between 0.5 
and 1.0 ng/ml. 
t2SI-EGF binding assays were performed essentially as described for 
t25I-ECGF binding assays. ~5I-EGF (sp act 6-8  x  104 cpm/ng) was added 
to a final saturating concentration of 20 ng/ml. Nonspecific binding was as- 
sessed in the presence of 102-fold molar excess unlabeled EGF and did not 
exceed 10%. 
ECGF Receptor Cross-linking Pro  tocol 
LEII cells were grown to confluence in 35-mm tissue culture plates and 
starved overnight in DME, 0.5%  ChFBS. The cells were incubated with 
routine gamma-IFN, alpha-ECGE or in combination for 20 h. The LEII 
cells were washed three times in cold binding buffer and incubated with 15 
ng/ml 125I-alpha-ECGF in 1.0 ml binding buffer.  After 2 h, the incubation 
medium was aspirated and the cells washed twice with cold binding buffer, 
and once with cold PBS. The cells were incubated further at 40C for 20 min 
with 1 ml of PBS containing 10 I11 of 30 mM DSS in DMSO. The cross- 
linking reaction was quenched with 20 ~tl of 2.0 M  Tris-HC1, pH 8.0, in 
the culture dish. The cells were scraped from the dish in 1 ml PBS and 
pelleted at 15,000 g for 10 s. The cell pellet was solubilized in 100 ltl of 50 
mM Tris, pH 7.3, containing 10 mM EDTA, 0.1 mM phenylmethylsulfonyl 
fluoride (PMSF), 200 mM NaCI,  1.0% (wt/vol) Triton X-100 (extraction 
buffer) at 4°C,  and insoluble material was removed by centrifugation at 
15,000 g for 10 min at 4°C. The supernatants were subjected to electrophore- 
sis using 7.5%  (wt/vol) SDS polyacrylamide slab gels as previously de- 
scribed (14). The gels were fixed, stained, destained, dried, and subjected 
to autoradiography as previously described (8). 
Results 
Gamma-In  terferon Inhibits Alpha-ECGF-induced 
Endothelial Cell Proliferation 
HUVEC seeded at 2  ×  103 cells/cm  2 in 35-mm dishes un- 
dergo a  15-20-fold  increase in cell number over a  10-12  d 
period in the presence of 50  ng/ml alpha-ECGF and FBS 
(Fig.  1 A). ECGF acts synergistically with FBS to promote 
HUVEC  proliferation  since  neither  ECGF  nor  FBS  can 
independently stimulate HUVEC growth (17).  Human na- 
tive gamma-IFN significantly inhibits alpha-ECGF-induced 
HUVEC proliferation at a concentration of 102 U/ml (Fig. 1 
A). The antiproliferative effect is due specifically to gamma- 
IFN because an anti-human gamma-IFN mAb completely 
blocked the growth inhibiting activity of gamma-IFN.  Ex- 
periments using recombinant human gamma-IFN produced 
similar results (data not shown). 
The  antiproliferative effects of  gamma-IFN  on  alpha- 
ECGF-induced HUVEC growth were concentration depen- 
dent with maximum inhibition occurring between  10  2 and 
10  3 U/ml  (data not shown).  The effects of gamma-IFN on 
HUVEC  were  reversible even  at  high  concentrations  of 
gamma-IFN. Human endothelial cell proliferation that had 
been inhibited by pretreatment with gamma-IFN for 4 d did 
resume alpha-ECGF-induced proliferation within 2-3 d af- 
ter the removal of gamma-IFN  from the culture medium 
(Fig. 2).  Furthermore, the antiproliferative effects of gam- 
ma-IFN on alpha-ECGF-induced HUVEC growth are par- 
tially overcome by the addition of 5  U/ml of heparin (Fig. 
1 B).  These data demonstrate that  ganuna-IFN  is an an- 
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Figure  1.  The  antiprolifera- 
tive effects of human gamma- 
IFN on alpha-ECGF-induced 
HUVEC growth and its rever- 
sal by heparin. HUVEC were 
seeded as described in Mate- 
rials and Methods. After 3 d, 
cells were treated as indicated. 
(A)  Cells  received  50  ng/ml 
ECGF (solid circles) 50 ng/ml 
ECGE and 103 U/ml gamma- 
IFN (solid squares),  103 U/ml 
gamma-IFN (solid triangles), 
or 10% FBS as a control (x). 
(B)  50  ng/ml  ECGF  and  5 
U/ml heparin (open  circles), 
50  ng/ml  ECGF,  103  U/ml 
gamma-IFN, and 5 U/ml hep- 
arin (open squares),  103 U/ml 
gamma-IFN, and 5 U/ml hep- 
arin (open triangles),  or 10 % 
FBS, and 5 U/ml heparin as a 
control  (x).  Ceils  were  har- 
vested and quantitated as de- 
scribed. All data are the mean 
of  duplicate  determinations 
+1  SD. 
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Figure  2.  The  antiprolifera- 
tive effects  of human gamma- 
IFN on alpha-ECGF-induced 
growth are reversible.  HUVEC 
were seeded at 2  x  104 cells 
per well in 35-ram plates and 
incubated in Medium 199 and 
10%  (vol/vol)  FBS  for  3  d. 
Cells  were  then  pretreated 
with  103  U/ml  gamma-IFN 
for 4 d with gamma-IFN add- 
ed  at  2-d  intervals.  On  day 
7,  gamma-IFN was  removed 
from  the  cultures  by  wash- 
ing the cell culture dishes with 
Medium  199  and  replaced 
with  50  ng/ml  ECGF (solid 
squares),  50  ng/ml  ECGF 
and  103  U/ml  gamma-IFN 
(solid  triangles),  10  3  U/ml 
gamma-IFN (solid circles), or 
a  10% FBS control (x).  Cells 
were  refed  with  these  addi- 
tions for an additional 6 d at 
2-d intervals. Cells were hap 
vested and quantitated at the 
indicated intervals as before. 
Data are the mean of duplicate 
determinations +1  SD. 
Friesel et al. Inhibition of Cell Proliferation by )'-Interferon  691 Figure 3. The gamma-IFN-induced HUVEC phenotype.  (A) HUVEC seeded at 2  x  104 cells per well in 35-mm dishes (low seed density 
HUVEC) and grown for 8 d in the presence of 50 ng/ml of ECGF.  (B) Low seed density  HUVEC grown for 8 d in the presence of 50 
ng/ml ECGF and 103 U/ml human gamma-IFN. (C) HUVEC grown to confluence,  then treated for 2 d with 50 ng/ml alpha-ECGF.  (D) 
HUVEC growth to confluence in 50 ng/ml ECGF,  then exposed  to 50 ng/ml ECGF plus  103U/ml gamma-IFN for 2 d.  Bar, 0.2 mm. 
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Figure 4.  The  effects of murine  gamma-IFN on  [3H]thymidine 
(dThd) incorporation by LEII cells. LEII cells were grown to con- 
fluence  in 48-well  plates  in  DME containing 5%  FBS and  5% 
ChFBS.  At confluence,  cells were starved  for 2 d with DME with 
0.5% ChFBS.  After 2 d, cells received 20 ng/ml ECGF with (solid 
circles) or without (open squares) varying concentrations  of native 
murine gamma-IFN. Cells were incubated  for 18 h at 37°C. After 
18  h,  cells  received  0.5  tlCi/well  [3H]thymidine  and  were  in- 
tagonist of ECGF-induced HUVEC growth and that the pro- 
cess is reversible. 
The Anffproliferative Effect of  Gamma-lFN 
Is Accompanied by a Morphological Alteration of  the 
Human Endothelial Cell Monolayer Phenotype 
Human endothelial cells possess a characteristic cobblestone 
polygonal morphology when propagated in the presence of 
FBS and ECGF (17, 32).  The incubation of gamma-IFN in 
either low cell density or confluent HUVEC cultures alters 
the morphology of the human endothelial  cell monolayer. 
Human endothelial cells exposed to gamma-IFN assume an 
elongated fibroblast-like morphology (Fig. 3, B and D). The 
gamma-IFN-induced endothelial cell phenotype is apparent 
after 2 d, and persists for as long as gamma-IFN and alpha- 
ECGF are present (up to 12 d). Upon removal of gamma-IFN 
from the  human  endothelial  cell  culture  and  replacement 
with  alpha-ECGF  and  FBS,  the  fibroblast-like  HUVEC 
cubated for an additional 4 h after which the radioactivity  incorpo- 
rated into cellular TCA-precipitable material  was determined.  The 
results shown are representative of five experiments performed with 
either  native  or recombinant murine  gamma-IFN.  Data are  the 
mean of duplicate  determinations. 
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within  2  d  (data not  shown).  These data  suggest that the 
antiproliferative and morphological events may indeed be 
related. 
100 
The Antiproliferative Effects of  Gamma-IFN Involve  ~_ 
the Inhibition of  Alpha-ECGF-induced DNA Synthesis  ~ 
Murine  lung capillary endothelial cells (LEII) incorporate 
[3H]thymidine into DNA in response to alpha-ECGF in a 
dose-dependent manner (2,  19). Half-maximum stimulation  ~  50 
of [3H]thymidine incorporation occurs between 0.5 and 1.0  -- 
ng/ml of alpha-ECGF (2). The addition of murine gamma- 
IFN  inhibits  alpha-ECGF-induced  [3H]thymidine  incor- 
poration by  LEII cells  (Fig.  4).  The inhibitory  effects of  II: 
gamma-IFN is also concentration dependent. LEII cells in-  ttl 
cubated with a high concentration of alpha-ECGF (20 ng/ml)  t" 
and varying concentrations of highly purified native murine 
gamma-IFN exhibit a  50%  reduction in [3H]thymidine in- 
corporation with as  little  as 5  ×  102  U/ml.  Recombinant 
murine gamma-IFN gave similar results (data not shown). 
The decrease in [3H]thymidine incorporation was not due to 
decreased  cell  viability  since  the  viable  cell  number  re- 
mained  constant  regardless  of treatment.  LEII cells  pre- 
treated with gamma-IFN for up to 30 h before the addition 
of ECGF also showed a marked inhibition of [3H]thyrnidine 
incorporation (data not shown), suggesting that the decrease 
in  [3H]thymidine  incorporation  is  due  to  a  decreased  re- 
sponsiveness of endothelial cells to ECGF rather than a delay 
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Figure 5.  Decreased  ~2~I-ECGF binding  to  Gamma-IFN-treated 
LEII cells is concentration  dependent.  LEII ceils were grown to 
confluence in 24-well plates and then starved for 24 h in DME con- 
taining 0.5 % ChFBS. LEII cells were incubated in the presence of 
various concentrations  of either native (open circles) or recom- 
binant (solid circles) murine gamma-IFN at 37°C for 18 h. After 
18 h, cells were washed three times with cold binding buffer, and 
incubated  with  15  ng/ml  125I-alpha-ECGF as  described  under 
Materials and Methods. All data are corrected for nonspecific bind- 
ing  in  the  presence  of 100-fold excess  unlabeled  alpha-ECGE 
Nonspecific binding  did not exceed  15%. Data are the mean of 
duplicate determinations,  and  are representative  of three  experi- 
ments. The standard deviation did not exceed 10% of the mean. 
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Figure 6.  Time  course  of 12~I-alpha-ECGF binding  activity  to 
LEII cells. LEII cells were grown to confluence in 24-well plates 
with DME containing  10%  ChFBS and incubated for 24 h with 
DME and 0.5 % ChFBS. Cells  were treated  with 5  x  103 U/ml 
murine-gamma-IFN (open circles), 100 ng/ml ECGF (x), or both 
(solid circles) for the  indicated  time  intervals.  The  cells  were 
washed three times with binding buffer at the end of these incuba- 
tion periods  and  t25I-alpha-ECGF or 125I-EGF binding were per- 
formed as described  in Materials and Methods.  The data are the 
mean of duplicate determinations and are representative of four ex- 
periments. The standard deviation did not exceed 10% of the mean. 
The solid triangle represents the binding of t25I-EGF after 16 h ex- 
posure of the endothelial cell population to murine  gamma-IFN. 
in the mitogenic response. These data are in good agreement 
with  the  antiproliferative  data  obtained  with  human  en- 
dothelial ceils by measuring viable cell number. 
Gamma-IFN Decreases the Binding of  ECGF 
to LEII Cells 
Endothelial cells possess a high affinity receptor for ECGF 
(26,  27)  which  is  rapidly  down-regulated  by  ligand  oc- 
cupancy (8, 26). We examined the ability of LEII cells treated 
with  gamma-IFN at  37°C  to  bind  125I-alpha-ECGE  The 
binding  of  ~25I-alpha-ECGF  to  gamma-IFN-treated  and 
control LEII cells was carried out at 4°C to minimize the 
effects of postreceptor binding events (internalization,  deg- 
radation,  etc.)  on the  quantitation  of ~25I-alpha-ECGF  re- 
ceptor binding.  Incubation at 37°C  for 20 h  with murine 
gamma-IFN decreased  the  ability  of  LEII cells  to  bind 
125I-alpha-ECGF  at saturating concentrations of ligand (Fig. 
5).  The effect of gamma-IFN on alpha-ECGF binding  to 
LEII cells was concentration dependent with a 50 % reduc- 
tion in binding occurring at 10-102 U  gamma-IFN per ml. 
This effect was obtained with either native murine gamma- 
IFN or recombinant murine gamma-IFN. Both preparations 
were equally potent in their ability to decrease alpha-ECGF 
binding to LEII cells (Fig. 5). These data correlate with the 
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clonal anti-gamma-IFN and together demonstrate that the 
effect of garnma-IFN on alpha-ECGF binding is due to gam- 
ma-IFN and not a minor contaminant of these preparations. 
The effect of gamma-IFN on alpha-ECGF binding to LEII 
cells was also time dependent  (Fig.  6).  Decreases in  ~25I- 
alpha-ECGF binding at saturation did not begin until at least 
3 h after exposure of LEII cells to gamma-IFN at 37°C.  Be- 
ginning  at  3  h  post-exposure to  gamma-IFN, there was a 
rapid decline in ~25I-alpha-ECGF binding for 3 h and then a 
more gradual decline for up to  16 h at which time binding 
decreased by 40-50%. These data contrast with the decrease 
in binding of ~25I-alpha-ECGF  to  cells pretreated with  100 
ng/ml  alpha-ECGF.  As  demonstrated  in  Fig.  6,  down- 
regulation of the ECGF receptor occurs very rapidly with a 
50% decrease in binding apparently within the first hour af- 
ter exposure to alpha-ECGF. In contrast, the binding of ~25I- 
EGF  is  not  altered  after  exposure  of endothelial  cells  to 
gamma-IFN for 16 h  (Fig. 6). In addition,  gamma-IFN did 
not affect the ability of EGF to down-regulate its own recep- 
tor (data not shown). 
Gamma-IFN did not influence the rate or degree of alpha- 
ECGF-induced  receptor  down-regulation  within  the  first 
hour.  Upon prolonged  incubation,  (up to 48  hours)  LEII 
cells treated with gamma-IFN did not significantly recover 
the ability to bind control levels of 125I-alpha-ECGF  (data 
not shown).  In addition,  LEII cells treated with both alpha- 
ECGF  and  gamma-IFN also  did  not  appreciably  recover 
t25I-alpha-ECGF binding after 48 h of incubation.  No effect 
on ~25I-alpha-ECGF  binding was observed when LEII cells 
were exposed to gamma-IFN  at 4°C instead of 37°C (data not 
shown). In contrast, when endothelial cells were treated with 
alpha-ECGF alone, binding decreased rapidly but returned 
to control values after 30 h of the initial exposure of alpha- 
ECGF (data not shown). In addition,  gamma-IFN does not 
compete with  125I-alpha-ECGF  for cross-linking  to  its  re- 
ceptor on LEII cells (8). 
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Figure 7. Gamma-IFN decreases  125I-ECGF  binding sites on LEII 
cells. (A) Confluent cultures of LEII cells in 24-well plates were in- 
cubated for 24 h in DME and 0.5% ChFBS.  Cells received 600 
U/ml recombinant gamrna-IFN (open circles) or no additions (solid 
circles) and were further incubated for 18 h at 37°C. The cells were 
washed three times with binding buffer and incubated at 4°C for 2 h 
with  various concentrations  of ~2SI-alpha-ECGF with  or without 
100-fold excess unlabeled ECGE Data are the mean of duplicated 
determinations  from a  representative experiment.  (B)  Scatchard 
analysis of  the binding data with (open circles) or without (solid  cir- 
cles) murine gamma-IFN. 
Figure 8. Gamma-IFN induces 
a decrease in the affinity cross- 
linking of the ECGF receptor 
on LEII cells. Confluent  mono- 
layers of LEII ceils in 35-ram 
dishes were starved for 24 h as 
previously described. Cultures 
received  no  treatment  (lane 
1),  500  U/ml  recombinant 
murine gamma-IFN (lane 2), 
50 ng/ml ECGF (lane 3), or 
500 U/ml IFN and 50 ng/ml 
ECGF (lane 4). After 20 h at 
37°C, cells were washed, cross- 
linked,  solubilized,  and electrophoresed  on 7.5% (vol/vol) SDS 
polyacrylamide gels as described in Materials and Methods. An au- 
toradiogram of the stained, dried gel is shown. 
Gamma-IFN Decreases the Number of 
ECGF Receptors 
To determine the basis for the decrease in alpha-ECGF bind- 
ing to gamma-IFN-treated LEII cells, the concentration de- 
pendence  of ~25I-alpha-ECGF  binding to control and gam- 
ma-IFN-treated cells was determined (Fig. 7 A). Scatchard 
analysis of the binding data reveals that gamma-IFN treat- 
ment results in a reduction in the total number of available 
receptors rather than a change in the affinity for the receptor 
(Fig. 7 B). Treatment of LEII cells with 6  x  102 U/ml garn- 
ma-IFN for 20 h at 37°C resulted in a decrease from 2.3  × 
104 to  1.0  ×  104 high affinity binding  sites per cell (Fig.  7 
B). Analysis of the binding data demonstrated an absence of 
a  significant change in the  affinity of 125I-alpha-ECGF  for 
its  receptor.  The dissociation constants  for control  versus 
gamma-IFN-treated LEII cells were 0.2 nM and 0.25 nM, 
respectively. 
Gamma-IFN Modulates the 150-kD Receptor for 
AIpha-ECGF 
Alpha-ECGF  binds  to  a  major  Mr  150,000 polypeptide 
receptor species on the  cell  surface of HUVEC  and LEII 
cells which possess an apparent M, of "o170,000 when mea- 
sured as cross-linked ligand-receptor complex (8). To deter- 
mine whether gamma-IFN modulates the ECGF  receptor, 
DSS-mediated cross-linking of bound ~25I-alpha-ECGF  was 
performed  on  LEII cells  exposed  to  either  gamma-IFN, 
ECGF, or both for 20 h.  As shown in Fig.  8, the treatment 
of LEII cells for 20 h with gamma-IFN results in an ,,o50% 
reduction in the Mr  170,000 ~25I-alpha-ECGF-ECGF recep- 
tor cross-linked species. Pretreatment of the LEII cells with 
100 ng/ml alpha-ECGF also resulted in a significant decrease 
in  the  cross-linked  ligand-receptor  polypeptide  complex. 
Particularly noteworthy is the fact that the combined treat- 
ment of LEII cells with gamma-IFN and ECGF resulted in 
the  greatest  decrease  in  specific  I25I-alpha-ECGF  cross- 
linking (Fig.  8). Also of interest is the presence of a minor 
Mr  150,000  polypeptide  ~25I-ECGF cross-linked  species 
which has been observed previously (8).  This polypeptide 
may result either from proteolysis of the larger Mr  170,000 
ligand-receptor complex or may indeed represent a second 
receptor (8). No other components were specifically labeled 
by  ~25I-alpha-ECGF  on  either  control  or  gamma-IFN- 
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ECGF receptor polypeptide is a  target for modulation by 
gamma-IFN on LEII cells. 
Discussion 
Gamma-IFN is a potent antiproliferative agent for normal 
and transformed cells in vitro (24,  33).  In an attempt to un- 
derstand the role of ECGF as a promoter of angiogenesis and 
elucidate its mechanism of action, we have investigated the 
role of gamma-interferon as an antagonist of ECGF-induced 
mitogenic activity in vitro. Gamma-IFN is shown to signifi- 
cantly inhibit ECGF-induced proliferation of HUVEC even 
at high concentrations of the polypeptide mitogen. In ad- 
dition, gamma-IFN also inhibits the incorporation of [3H]- 
thymidine into DNA  from ECGF-stimulated murine lung 
capillary endothelial cells in vitro.  We attribute the anti- 
proliferative properties  of gamma-IFN on ECGF-induced 
mitogenesis specifically to gamma-IFN since mAb's to gam- 
ma-IFN block the antagonism, and recombinant gamma- 
IFN had the same effect. 
The antiproliferative effects observed with gamma-IFN on 
endothelial cells in vitro persists for as long as gamma-IFN 
is present, and upon its removal, the endothelial cells again 
become responsive to ECGE The effects of gamma-IFN on 
ECGF-induced  HUVEC  proliferation  could  be  partially 
overcome by the addition of 5 U/ml of heparin. Although the 
mechanism of glycosaminoglycan reversion is not known, 
gamma-IFN, like ECGF, does bind to heparin (1). Thus, fur- 
ther  experiments  on  the  structural  interaction  between 
gamma-IFN and heparin are required since it is not clear 
whether the same glycosaminoglycan  in the heparin prepara- 
tion is responsible for the structural interaction between lym- 
phokine and the growth factor. 
Recently, gamma-IFN has been shown to have a variety of 
biological effects on human endothelial cells. Gamma-IFN 
has been demonstrated to (a) induce elevated levels of major 
histocompatability antigens on endothelial cells (4, 23), (b) 
modulate the expression  of a  unique extracellular matrix 
(20), and (c) induce a unique morphological endothelial cell 
phenotype in vitro (22).  Here, we confirm the observation 
that gamma-IFN alters the endothelial cell monolayer  pheno- 
type, by inducing an elongated fibroblast-like morphology 
which contrasts with the normal "cobblestone" appearance of 
the endothelial cell in vitro. The gamma-IFN-induced phe- 
notype is reversible upon removal of gamma-IFN from the 
culture medium. It is of interest to note that the gamma- 
IFN-induced phenotype resembles  the Stage I  phenotype 
which human endothelial cells assume before the formation 
of the organized or nonterminal-differentiated phenotype in 
vitro (7,  16,  18, 21). This correlation between phenotypes 
may be significant since the differentiated phenotype and the 
gamma-IFN-induced  phenotype  are  nonproliferative and 
both phenotypes are refractory to the mitogenic attributes of 
ECGF (16, 18). These observations argue that some stages 
in neovascularization may not involve the proliferation of en- 
dothelial cells, but rather involve endothelial cell migration 
and organization. 
• The exposure of endothelial cells to low concentrations of 
gamma-IFN results in an inhibition of alpha-ECGF-induced 
endothelial cell proliferation and [3H]thymidine incorpora- 
tion. The inhibition of ECGF-induced endothelial cell prolif- 
eration correlates with a decrease in the number of ECGF 
receptors present on the surface of the endothelial cell with 
no significant change in receptor affinity. Gamma-IFN also 
modulates the Mr 150,000 ECGF receptor polypeptide which 
is present on the endothelial cell surface (8).  The exposure 
of  the endothelial cell to ganuna-IFN results in an r~50 % de- 
crease  in  the  amount of the cross-linked receptor-ligand 
complex.  The  decrease  in  125I-ECGF binding  and cross- 
linking to endothelial ceils upon exposure to gamma-IFN is 
not due to a general inhibition of protein synthesis since en- 
dothelial cells exposed to gamma-IFN have increased levels 
of protein synthesis above those for control quiescent en- 
dothelial cells (Friesel, R., and T. Maciag, unpublished ob- 
servations). The correlation between the modulation of the 
ECGF receptor on the endothelial cell surface by gamma- 
IFN in a concentration-, time-, and temperature-dependent 
manner with the kinetics of the gamma-IFN-induced antag- 
onism confirms our initial observation which demonstrated 
that the presence of the ECGF receptor on the endothelial 
cell surface is essential for the stimulation of endothelial cell 
proliferation (26). 
Several lines of evidence demonstrate that the modulation 
of the ECGF receptor by gamma-IFN does not result from 
a direct interaction of gamma-IFN with the ECGF receptor. 
First,  we have demonstrated previously that gamma-IFN 
cannot compete either for ~I-alpha-ECGF binding or cross- 
linking to the Mr 150,000 ECGF receptor (8). Other studies 
(25, 35) have demonstrated that murine gamma-IFN and hu- 
man ganuna-IFN bind to unique and specific high affinity 
membrane receptors (25,  35).  Furthermore, affinity cross- 
linking of ~25I-gamma-IFN to  sensitive cell  lines demon- 
strate that the gamma-IFN cross-linked receptor complex 
possesses  an Mr of ~110,000  on both human and murine 
cells (25, 35) and is therefore, distinct from the Mr 150,000 
ECGF  receptor  polypeptide  (8).  Finally,  the  kinetics  of 
ECGF receptor down-regulation by gamma-IFN in the ab- 
sence of ECGF is unique.  ECGF-induced receptor down- 
regulation results in a 50 % reduction in L25I-ECGF binding 
within the first hour after the addition of ECGE  whereas 
gamma-IFN  treatment requires  16-20  h  to  yield a  50% 
reduction in ~25I-ECGF binding. Because the mechanism of 
gamma-IFN-induced down-regulation of the ECGF recep- 
tor does not involve the interaction of gamma-IFN with the 
ECGF receptor, it is reasonable to suggest that the mecha- 
nism may involve gamma-IFN-induced signal transduction 
mediated by the gamma-IFN receptor and directed, in part, 
toward uncoupling the mitogenic signal induced by ECGF. 
This is consistent with the kinetics of the down-regulation of 
the transferrin receptor on mouse peritoneal macrophages by 
gamma-IFN which involves the activation of protein kinase 
C (10, 34).  Although it is not known whether the antagonist 
effects initiated by gamma-IFN on endothelial cells involve 
protein kinase C, it is of interest to note that phorbol esters, 
which are potent stimulators of intracellular protein kinase 
C, (a) inhibit endothelial cell proliferation, (b) induce an en- 
dothelial cell phenotype in vitro  which  is  similar to  the 
gamma-IFN-induced phenotype (Friesel, R., R. Lyall, and 
T. Maciag, unpublished observations), and (c) stimulate the 
organizational behavior of endothelial cells in vitro (21). 
It is difficult to eliminate the possibility that the effect of 
Friesel  et al. Inhibition of Cell Proliferation by y-lnterferon  695 ganuna-IFN as an antagonist of endothelial cell proliferation 
also  involves  the  down-regulation  of other  growth  factor 
receptors present on the endothelial cell surface.  However, 
in this regard, we have not observed any significant alteration 
in the binding of ~I-EGF  to endothelial cells after treat- 
ment with gamma-IFN. Similarly, beta-TGE  a potent inhibi- 
tor of mink lung epithelial cell proliferation,  has recently 
been shown to exert an antiproliferative  effect on these cells 
without an alteration of EGF receptor binding or phosphory- 
lation (15). In addition, beta-TGF has recently been shown 
to inhibit  endothelial cell proliferation in vitro (U). There- 
fore, it appears  that endothelial cell proliferation is tightly 
regulated  by antiproliferative  factors  that exert their effects 
on cells at various levels which may include the modulation 
of growth factor  receptors. 
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